Daratumumab

Generic Name
Daratumumab
Brand Names
Darzalex, Darzalex Faspro
Drug Type
Biotech
Chemical Formula
-
CAS Number
945721-28-8
Unique Ingredient Identifier
4Z63YK6E0E
Background

Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...

Indication

Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.

Associated Conditions
Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Associated Therapies
-
Clinical Trials
Related News

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

First Posted Date
2024-05-10
Last Posted Date
2024-05-10
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
45
Registration Number
NCT06409702

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY

First Posted Date
2024-04-10
Last Posted Date
2024-06-20
Lead Sponsor
Children's National Research Institute
Target Recruit Count
12
Registration Number
NCT06358638
Locations
🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

First Posted Date
2024-04-08
Last Posted Date
2024-04-08
Lead Sponsor
Nantes University Hospital
Target Recruit Count
103
Registration Number
NCT06353022
Locations
🇫🇷

CHU Montpellier, Montpellier, France

🇫🇷

CH Lyon Sud, Lyon, France

🇫🇷

CH de la Côte Basque, Bayonne, France

and more 17 locations

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

First Posted Date
2024-04-04
Last Posted Date
2024-10-11
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
39
Registration Number
NCT06348147
Locations
🇺🇸

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

First Posted Date
2024-03-01
Last Posted Date
2024-11-21
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
15
Registration Number
NCT06287944
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

First Posted Date
2024-01-31
Last Posted Date
2024-05-31
Lead Sponsor
Celgene
Registration Number
NCT06232707
Locations
🇺🇸

Local Institution - 0088, Los Angeles, California, United States

🇺🇸

Local Institution - 0324, Baltimore, Maryland, United States

🇦🇺

Local Institution - 0022, Waratah, New South Wales, Australia

and more 167 locations

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

First Posted Date
2024-01-05
Last Posted Date
2024-02-06
Lead Sponsor
Jin Lu, MD
Target Recruit Count
41
Registration Number
NCT06192979
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

First Posted Date
2024-01-05
Last Posted Date
2024-04-23
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
200
Registration Number
NCT06189833
Locations
🇬🇷

St Savvas Cancer Hospital, Athens, Greece

🇩🇪

Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany

🇦🇹

Innsbruck Medical University, Innsbruck, Austria

and more 28 locations

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

First Posted Date
2023-12-27
Last Posted Date
2024-12-11
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
559
Registration Number
NCT06182774
Locations
🇨🇦

BCCA - Kelowna, Kelowna, British Columbia, Canada

🇨🇦

Verspeeten Family Cancer Centre, London, Ontario, Canada

🇨🇦

Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada

and more 15 locations

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

First Posted Date
2023-12-13
Last Posted Date
2024-10-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
70
Registration Number
NCT06169215
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States

🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 23 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy